• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Slowing Growth Concerns Around Waters’ ESOP Shelf Registration Might Change The Case For Investing In WAT

    Simply Wall St·03/05/2026 02:35:29
    Listen to the news
    • Waters Corporation recently filed a US$116.67 million shelf registration for 350,000 common shares tied to an employee stock ownership plan and earlier this month presented at TD Cowen’s 46th Annual Health Care Conference in Boston, led by President and CEO Udit Batra.
    • These developments come as investors weigh concerns about Waters’ slowing 2.1% organic revenue growth, shrinking adjusted operating margins, and a weaker return on invested capital over the past two years.
    • We’ll now examine how the concerns over slowing organic revenue growth could reshape Waters’ previously optimistic investment narrative and outlook.

    Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

    Waters Investment Narrative Recap

    To own Waters today, you need to believe that its core analytical instruments and the planned BD Biosciences and Diagnostic Solutions combination can still support durable growth, even as organic revenue has recently slowed to 2.1% and margins and ROIC have come under pressure. The new US$116.67 million ESOP shelf and the TD Cowen conference appearance do not materially change the near term focus, which remains execution on integration and stabilizing profitability.

    The ESOP related shelf registration is the most relevant recent development here, as it reinforces ongoing equity based compensation at a time when shareholders have already experienced dilution and are watching margin compression and weaker ROIC. For investors, this sits alongside the BD integration and cost synergy targets as a key backdrop when assessing whether Waters can convert its higher revenue guidance into healthier earnings quality and improved returns over the next few years.

    Yet beneath the potential upside from BD synergies, investors should be aware that persistent weakness in core markets and margin pressure could...

    Read the full narrative on Waters (it's free!)

    Waters' narrative projects $3.7 billion revenue and $946.3 million earnings by 2028. This requires 6.4% yearly revenue growth and a $284.9 million earnings increase from $661.4 million today.

    Uncover how Waters' forecasts yield a $394.68 fair value, a 24% upside to its current price.

    Exploring Other Perspectives

    WAT 1-Year Stock Price Chart
    WAT 1-Year Stock Price Chart

    Compared with the consensus view, the most cautious analysts were already assuming only about 5.9 percent annual revenue growth to roughly US$3.6 billion and slower margin progress, suggesting that if pharma and academic demand or BD integration stumbles, the story could look very different from what you might expect today.

    Explore 2 other fair value estimates on Waters - why the stock might be worth as much as 34% more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.